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A Mutation in C2orf64 Causes Impaired Cytochrome c
Oxidase Assembly and Mitochondrial Cardiomyopathy
Merei Huigsloot,1,2 Leo G. Nijtmans,1,2 Radek Szklarczyk,3 Marieke J.H. Baars,4
Marie¨l A.M. van den Brand,1,2 Marthe G.M. HendriksFranssen,1,2 Lambertus P. van den Heuvel,1,2
Jan A.M. Smeitink,1 Martijn A. Huynen,3 and Richard J.T. Rodenburg1,2,*
The assembly of mitochondrial respiratory chain complex IV (cytochrome c oxidase) involves the coordinated action of several assembly
chaperones. In Saccharomyces cerevisiae, at least 30 different assembly chaperones have been identified. To date, pathogenic mutations
leading to a mitochondrial disorder have been identified in only seven of the corresponding human genes. One of the genes for which
the relevance to human pathology is unknown is C2orf64, an ortholog of the S. cerevisiae gene PET191. This gene has previously been
shown to be a complex IVassembly factor in yeast, although its exact role is still unknown. Previous research in a large cohort of complex
IV deficient patients did not support an etiological role of C2orf64 in complex IV deficiency. In this report, a homozygous mutation in
C2orf64 is described in two siblings affected by fatal neonatal cardiomyopathy. Pathogenicity of the mutation is supported by the results
of a complementation experiment, showing that complex IVactivity can be fully restored by retroviral transduction of wild-typeC2orf64
in patient-derived fibroblasts. Detailed analysis of complex IV assembly intermediates in patient fibroblasts by 2D-BN PAGE revealed the
accumulation of a small assembly intermediate containing subunit COX1 but not the COX2, COX4, or COX5b subunits, indicating that
C2orf64 is involved in an early step of the complex IVassembly process. The results of this study demonstrate that C2orf64 is essential for
human complex IV assembly and that C2orf64mutational analysis should be considered for complex IV deficient patients, in particular
those with hypertrophic cardiomyopathy.Identification of the disease-causing mutation in patients
with amitochondrial disorder due to cytochrome c oxidase
(complex IV) deficiency (MIM 220110) is complicated by
the sheer number of candidate genes. Mutations in
mtDNA-encoded genes MT-CO1, MT-CO2, and MT-CO3,
as well as MT-TS1 and MT-TL1, have been identified,
although these are relatively rare.1 Remarkably, mutations
in the ten nuclear-encoded structural complex IV subunits
appear to be even rarer because only one case has been
described to date.2 The majority of deficiencies are caused
by mutations in nuclear genes encoding proteins involved
in the synthesis and assembly of complex IV. These include
TACO1 (MIM 612958), a translational activator of COX1;3
LRPPRC (MIM 607544) that stabilizes COX1 and 3
mRNA;4,5 COX10 (MIM 602125) and COX15 (MIM
603646) that are involved in heme A biosynthesis;6,7
SCO1 (MIM 603644) and SCO2 (MIM 604272) that cata-
lyze copper insertion into COX2;8–10 and SURF1 (MIM
185620) that is involved in early maturation of
COX1.11,12 Despite the progress that has been made in
understanding the mechanism of complex IV assembly,
many complex IV deficient cases remain unsolved at the
molecular genetic level. Thus, in yeast, many more
assembly factors that have human orthologs have been
identified, including Cox11p, Cox16p, Cox17p, Cox19p,
and Pet191p. Some of the human orthologs of the
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However, no mutations have been found thus far, suggest-
ing that these genes might not be relevant to human
pathology.13,14
The study described here has been carried out in the
Netherlands in accordance with the applicable rules con-
cerning the review of research ethics committees of the
Radboud University Nijmegen Medical Center and
informed consent. This report describes two patients
from a consanguineous family of Turkish origin. The first
child was born by Caesarian section because of fetal stress
after 39 weeks of an uneventful pregnancy. The patient
died on day 8 after birth because of hypertrophic cardio-
myopathy of the left and right ventricles. During the
next pregnancy, an ultrasound examination performed at
week 34 revealed signs of fetal cardiomyopathy. The girl
was born at week 36 by caesarean section because of fetal
stress. On day 10 after birth, this patient also died because
of hypertrophic restrictive cardiomyopathy. For both
patients, functional impairment of brain or skeletal
muscle, often observed in complex IV deficiency,15
were not documented. Postmortem microscopic investiga-
tions showed accumulation of lipid droplets in cardiomyo-
cytes and mitochondrial proliferation. Measurements of
the mitochondrial respiratory chain enzyme activities
were performed by previously described methods16,17
in cultured fibroblasts of patient P1 revealed a severeadboud University Nijmegen Medical Centre, PO Box 9101, NL-6500HB,
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Table 1. Activity of Respiratory Chain Enzymes in Fibroblasts from
Patient P1
Enzyme Enzyme Activitya Control Rangea
Complex I 150 100–310
Complex II 528 520–845
Complex III 1523 1320–2610
Complex IV 150 680–1190
Citrate synthase 206 144–257
Patient P1 is homozygous for the c.157G>C mutation in C2orf64.
a Activities of complex I, complex II, complex III, and complex IV are expressed
as milliunits per unit citrate synthase (CS); activity of citrate synthase is
expressed as milliunits per milligram protein.complex IV deficiency (Table 1). The activity of complex IV
in cultured fibroblasts and in heart muscle was reduced as
well (Table 2). In the same family, two subsequent preg-
nancies were tested for the presence of complex IV defi-
ciency by measuring enzyme activities in native chorionic
villi.18 The activities in both the chorionic villi and in
cultured fibroblasts obtained from skin biopsies collected
after birth revealed (near-) normal complex IV activities
(Table 2). Genetic analysis did not reveal mutations in
the mtDNA and in the nuclear genes known to cause
complex IV deficiency, including SCO1, SCO2, COX10,
and COX15. Subsequently, homozygosity mapping was
performed on the index case patient P1 (VI-1 in
Figure 1A), patient P2 (VI-2 in Figure 1A), and the two
healthy siblings (VI-3 and VI-4 in Figure 1A), revealing
a large candidate region on chromosome 2 (73.28–145.07
Mb). This region, containing a total of 710 genes, was
screened for known human complex IV genes as well as
for human orthologs of yeast genes encoding known
complex IV assembly and maintenance proteins. Only
one candidate gene is present in this region, C2orf64, the
human ortholog of PET191. It has been shown that
complex IV activity is deficient in yeast pet191D mutant
strain, whereas the activity of succinate:cytochrome c
oxidoreductase (complex IIþIII) is elevated, and complexTable 2. Activity of Complex IV in Tissues and Cultured
Fibroblasts from Patients and Healthy Sibling
Patient or
Healthy Sibling Genotypea Tissue
Complex IV
Activityb
Control
Rangeb
Patient P2 mut/mut heart 4 114–424
fibroblasts 16 680–1190
Healthy sibling S3 wt/mut chorionic villi 269 271–922
fibroblasts 623 680–1190
Healthy sibling S4 wt/wt chorionic villi 557 271–922
fibroblasts 714 680–1190
a Genotype refers to the presence of wild-type (wt) or c.157G>C mutated
(mut) C2orf64 alleles.
b The activity of complex IV is expressed as milliunits per unit citrate synthase.
The AmIII and V protein levels are unaffected.19 This indicates
that mitochondrial translation in pet191D cells is normal,
yet levels of Cox1p, Cox2p, and Cox3p protein were found
to be reduced. From these findings, it was concluded that
Pet191p is a complex IV assembly protein in yeast.19 In
a previously published study of this gene in a large cohort
of complex IV deficient patients, no mutations were
observed.14 We found a homozygous mutation at
c.157G>C (p.Ala53Pro) in C2orf64 (NM_001008215.1) in
the two affected children, whereas healthy sibling S3 was
heterozygous for this mutation, and healthy sibling S4
carried two wild-type alleles (Figure 1B). This was in agree-
ment with the homozygosity mapping data (Table S1).
Both parents were heterozygous for the mutation. This
mutation was not detected in 216 alleles of healthy control
individuals of Turkish origin, nor is it present in EST data-
bases, consistent with pathogenicity of the mutation. In
order to assess whether the C2orf64 p.Ala53Pro mutation
had an effect on complex IV assembly, we performed 1D
and 2D blue native PAGE (BN-PAGE) analysis on fibro-
blasts of the two patients and their healthy siblings. One-
dimensional BN-PAGE showed that both the activity and
amount of holocomplex complex IV was strongly reduced
in both patients compared to the siblings (Figure 2A). Two-
dimensional BN-PAGE analysis subsequently confirmed
the near absence of holocomplex IV and showed COX1
accumulation in subcomplexes (Figure 2C). Complex IV
assembly is a stepwise process with three milestones in
the form of subassemblies S1, S2, and S3 that are formed
by the sequential addition of subunits and cofactors.20,21
The predominant subcomplex in the C2orf64 patients
was similar in size to the smallest subcomplex observed
in control cells (Figure 2C). This subcomplex appears to
be similar to the previously described subcomplex S122
that has also been observed in complex IV deficiency due
to mutations in the gene-encoding assembly factor
SURF1,23,24 although these patients also show a varying
degree of accumulation of subcomplex S2, the next
subassembly in the complex IV assembly pathway. The
levels of individual complex IV subunits COX1, COX2,
COX4, and COX5a were also reduced (Figure 2B), which
suggests that the very low levels of holocomplex IV and
absence of higher order assembly intermediates beyond
subcomplex S1 results in downregulation or destabiliza-
tion of individual complex IV subunits. The reduced levels
of COX1 and COX2 are compatible with the reduced levels
of the yeast orthologs in Pet191p deficient yeast cells.19
Taken together, these observations suggest a role for
C2orf64 in an early stage of the complex IV assembly
process.
To confirm that the mutation in C2orf64 caused
the strong reduction of complex IV holocomplex
amount and activity, we retrovirally transduced both
index patient and healthy sibling fibroblasts with
human full-length C2orf64. Complementation of patient
fibroblasts with wild-type C2orf64 resulted in normal-
ization of fully assembled complex IV (Figure 3).erican Journal of Human Genetics 88, 488–493, April 8, 2011 489
Figure 1. Family Pedigree andMolecular
Genetic Analysis of the C2orf64 cDNA
(A) Pedigree of the family of the two
patients described in this report.
(B) Electropherograms showing the wild-
type sequence of C2orf64 (top panel) and
the nucleotide changes in the complex IV
deficient patients P1 (VI-1 in A) and P2
(VI-2) and the healthy siblings S3 (VI-3)
and S4 (VI-4). The arrow indicates the
mutated nucleotide c.157G>C. P1 and P2
are homozygous for the c.157G>C muta-
tion, whereas S3 is a heterozygous carrier
and S4 carries the wild-type sequence.
Please note that the reverse sequence is
shown.Moreover, normal in-gel activity of complex IV was
present in fibroblasts from the healthy siblings and in
the C2orf64-complemented patient cell line (Figure 3).
Overexpression of wild-type C2orf64 in healthy siblings
had no effect on complex IV levels or activity (Figure 3).
These observations support the notion that the mutationtion of a COX1 containing early complex IV assembly intermediat
different antibodies can only be compared qualitatively because exp
490 The American Journal of Human Genetics 88, 488–493, April 8, 2in C2orf64 is responsible for the complex IV deficiency in
our patients.
Further support for the pathogenic role of the
p.Ala53Pro mutation came from protein sequence anal-
ysis. The C2orf64 protein contains two Cx9C motifs that
are highly conserved among all eukaryotes with complexFigure 2. Reduced Complex IV Activity
and Amount in Fibroblasts from the
Patients with a C2orf64 Mutation
(A) Fibroblasts from patients P1 and P2
show a severely reduced in-gel activity of
complex IV32 compared to the unaffected
siblings S3 and S4 (top panel). The
lower three panels show the results
of immunoblots after nondenaturing
BN-PAGE,33 revealing a severely reduced
complex IV amount in patients P1 and
P2. Complex IV was stained with anti-
COX4 antibodies. Equal loading of the
gel was tested by staining for complex III
(by using anti-CORE2) and complex II
(by using anti-70 kDa subunit). Holocom-
plex IV is indicated by the arrowhead;
the asterisk indicates a nonspecific band.
(B) Immunoblot after SDS-PAGE of fibro-
blast extracts of patients P1 and P2 and
healthy siblings S3 and S4 showing
reduced expression levels of complex IV
subunits COX1, COX2, COX4, and
COX5a in fibroblasts of both patients.
The complex II 70 kDa subunit (CII
70 kDa) was used as a loading control.
(C) Two dimensional BN-PAGE analysis of
fibroblasts from patients P1 and P2 and the
healthy siblings S3 and S4 was performed
in accordance with standard procedures.
Blots were stained by using antibodies
against different complex IV subunits as
indicated. Holocomplex IV is indicated
(H). Patients P1 and P2 show accumula-
tion of a small subcomplex (indicated by
S1) that contains COX1 but not COX2,
COX4, and COX5a. This indicates that
mutation of C2orf64 results in accumula-
e. Note that blots of different fibroblasts and blots stained with
osure times are not the same.
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Figure 3. Complementation with Wild-Type C2orf64 Restores
Complex IV
Fibroblasts from patient P2 and healthy siblings S3 and S4 were
infected with retrovirus containing no insert (pDS) or C2orf64
(C2). The C2orf64 complementation was done by cloning full
length human C2orf64 cDNA clone IOH26651 (GeneID:
493753; Imagenes, Berlin, Germany) into the Gateway retroviral
destination vector pDS_FBneo (# MBA-295, LGC, Middlesex, UK)
with the Gateway LR Clonase II enzyme mix (Invitrogen).
Recombinant viruses were produced by using the amphotropic
packaging cell line PA317 (#CRL-9078, LGC, Middlesex, UK)
according to the manufacturer’s protocol (Invitrogen, Breda,
The Netherlands). P2, S3, and S4 fibroblasts were incubated for
24 hr with a 1:1 mixture of growth medium and virus-containing
medium in the presence of 4 mg/ml polybrene,34 followed by
14 days selection with 500 mg/ml geneticin (G418, PAA, Pasching,
Austria). G418-resistant cells were used for biochemical analyses
within 5 passages after transduction. P2 fibroblasts grew very
slowly and all cells failed to survive the selection procedure
upon retroviral transduction of the empty vector. Mitochon-
drion-enriched fractions from all other transduced cell lines
were tested for in-gel activity of complex IV after BN-PAGE. In
addition, amounts of OXPHOS complexes were visualized with
anti-NDUFA9 (complex I; CI), anti-70 kDa subunit of complex
II (CII), anti-CORE2 for complex III (CIII), anti-COX1 for
complex IV (CIV) and anti-complex Va for complex V (CV).
The results show a clear complex IV deficiency, consistent with
the results in Figure 2A, which is rescued by complementation
with wild-type C2orf64 (indicated by C2). Lanes indicated with
wt are nontransduced fibroblasts, lanes with pDS indicate fibro-
blasts transduced with empty virus. Note that the complex III
panel shows three bands, the lowest of which represents holo-
complex III, whereas the two more slowly migrating bands
most likely represent supercomplexes containing complex III.
The middle band is absent in patient P2 and returns after comple-
mentation with wild-type C2orf64. This middle band therefore
most likely represents a supercomplex containing complex III
and complex IV.IV (Figure 4A). In twin Cx9C motif proteins with a known
3D structure, COX17 and COX6b, the cysteines in these
motifs form intramolecular disulfide bridges that stabilize
two antiparallel a helices in a hairpin conformation.25,26
If C2orf64 adopts such a helical hairpin structure, the
p.Ala53Pro mutation will have a significant influence on
protein structure, because proline residues lack an amide
proton, precluding the hydrogen bond required for theThe Amformation of a-helices.27 Additionally, sterical interference
of the proline sidechain with the a-helix backbone28
restricts the presence of prolines to the first four positions
of a helix.27 Indeed, analysis of eukaryotic orthologs of
not only Pet191p (Figure 4A) but also all other 23 human
mitochondrial twin Cx9C proteins shows that prolines
appear exclusively within the first four residues of a helices
(data not shown). In contrast, the p.Ala53Pro mutation is
present at the seventh position and is likely to interfere
with its conformation (Figure 4B). Consistent with the
predicted structure of Pet191p, the first cysteine (C14) of
the first Cx9C motif and the second cysteine (C57) of
the second Cx9C motif, which are predicted to interact
with each other, have been shown to be essential for
respiration in yeast.19 Thus, the p.Ala53Pro mutation in
C2orf64 is likely to interfere with the oxidative folding
process of this twin Cx9C domain-containing protein
that is linked to its mitochondrial inter membrane space
localization.29–31Supplemental Data
Supplemental Data include one table and can be found with this
article online at http://www.cell.com/AJHG/.Acknowledgments
Part of this work was supported by a grant from the Innovatieger-
ichte Onderzoeksprogramma’s Genomics program of Senterno-
vem (Grant IGA05003 to M.H.) and the Netherlands Genomics
Initiative (Horizon Program to R.S.). The authors thank Cindy
Dieteren for assistance with the Gateway cloning, Hanka Vense-
laar for helpful suggestions on structure-function relationship,
and the colleagues of the muscle and tissue culture labs of the
Laboratory of Genetic, Endocrine, and Metabolic Diseases for
excellent technical assistance.
Received: December 21, 2010
Revised: February 21, 2011
Accepted: March 2, 2011
Published online: March 31, 2011Web Resources
The URLs for data presented herein are as follows:
GenBank, http://www.ncbi.nlm.nih.gov/Genbank
NCBI database, http://www.ncbi.nlm.nih.gov
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi.
nlm.nih.gov/OmimReferences
1. Shoubridge, E.A. (2001). Cytochrome c oxidase deficiency.
Am. J. Med. Genet. 106, 46–52.
2. Massa, V., Fernandez-Vizarra, E., Alshahwan, S., Bakhsh, E.,
Goffrini, P., Ferrero, I., Mereghetti, P., D’Adamo, P., Gasparini,
P., and Zeviani, M. (2008). Severe infantile encephalomyop-
athy caused by a mutation in COX6B1, a nucleus-encodederican Journal of Human Genetics 88, 488–493, April 8, 2011 491
p.Ala53Pro 
Cx9C Cx9C
53
C
A
E
S
Y
N
F
K
C
L
F
P
47
57
A
B
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